EGFR and non-small cell lung carcinoma: The phase 3 FLAURA trial established osimertinib as the standard first-line therapy for EGFRm advanced NSCLC given prolonged PFS compared with standard EGFR-TKIs (18.9 vs. 10.2 months, HR 0.46, CI 95% 0.37–0.57, p < 0.0001) [13].